ArticleNaunyn-Schmiedeberg's archives of pharmacology2025
Gastrodin inhibits hexokinase-2 mediated glycolysis to rescue rotenone-damaged PC12 cells.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- High Glucose Aggravates Cerebral Ischemia/Reperfusion via Truncated NLRP3-Mediated Hexokinase-2 Translocation.CNS neuroscience & therapeutics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Glycolysis, a fundamental pathway in cellular energy metabolism, exhibits dysregulation that is intricately linked to the pathogenesis of Parkinson's disease (PD). Although the compensatory upregulation of aerobic glycolysis helps sustain ATP levels, its precise effects on dopaminergic neurons remain poorly understood. This study investigated the mechanism of rotenone-induced injury in PC12 cells and explored the potential protective effect of gastrodin. We found that rotenone exposure significantly enhanced glycolysis, with increased lactate production, lactate dehydrogenase (LDH) activity and decreased pyruvate concentrations. However, gastrodin treatment effectively attenuated rotenone-induced glycolysis, normalizing lactate production, LDH activity, and pyruvate levels. Furthermore, gastrodin inhibited the increase in glycolytic enzymes hexokinase 2(HK2), Pyruvate kinase M2(PKM2), and Lactate dehydrogenase A(LDHA) levels induced by rotenone. Notably, the combination of the HK2-specific inhibitor 2-DG with gastrodin demonstrated synergistic effects in inhibiting rotenone-induced glycolysis in PC12 cells. These findings collectively indicated that HK2-mediated aberrant glycolysis plays a pivotal role in rotenone-induced cell death, and that gastrodin confers neuroprotection through modulation of this metabolic pathway.
Indexed as
Identifiers
40464941What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.